These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 19358084)

  • 1. Modeling thyroid cancer in the mouse.
    Zhu XG; Cheng SY
    Horm Metab Res; 2009 Jun; 41(6):488-99. PubMed ID: 19358084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic alterations in thyroid cancer: the role of mouse models.
    Knostman KA; Jhiang SM; Capen CC
    Vet Pathol; 2007 Jan; 44(1):1-14. PubMed ID: 17197619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas.
    Moraitis D; Karanikou M; Liakou C; Dimas K; Tzimas G; Tseleni-Balafouta S; Patsouris E; Rassidakis GZ; Kouvaraki MA
    Surgery; 2014 Dec; 156(6):1542-8; discussion 1548-9. PubMed ID: 25456951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poorly Differentiated and Undifferentiated Thyroid Carcinomas.
    Eloy C; Ferreira L; Salgado C; Soares P; Sobrinho-Simões M
    Turk Patoloji Derg; 2015; 31 Suppl 1():48-59. PubMed ID: 26177317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies.
    Pishkari S; Paryan M; Hashemi M; Baldini E; Mohammadi-Yeganeh S
    J Endocrinol Invest; 2018 Mar; 41(3):269-283. PubMed ID: 28762013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cytokeratin expression of benign and malignant epithelial thyroid gland tumors. An immunohistologic study of 154 neoplasms using 8 different monoclonal cytokeratin antibodies].
    Schröder S; Wodzynski A; Padberg B
    Pathologe; 1996 Nov; 17(6):425-32. PubMed ID: 9082363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
    McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
    Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial follicular cell tumors: classification and morphological characteristics.
    Nosé V
    Endocr Pathol; 2010 Dec; 21(4):219-26. PubMed ID: 20878367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy: a new hope for thyroid carcinomas.
    Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Medullary thyroid carcinoma and other rare types of thyroid carcinoma].
    Obara T
    Nihon Rinsho; 2007 Nov; 65(11):2087-91. PubMed ID: 18018575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
    Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
    J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood group antigen expression in malignant tumors of the thyroid: a parallel between medullary and nonmedullary carcinomas.
    Larena A; Vierbuchen M; Fischer R
    Langenbecks Arch Chir; 1995; 380(5):269-72. PubMed ID: 7500798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment.
    Begum S; Rosenbaum E; Henrique R; Cohen Y; Sidransky D; Westra WH
    Mod Pathol; 2004 Nov; 17(11):1359-63. PubMed ID: 15195111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.
    Nikiforov YE
    Endocr Pathol; 2004; 15(4):319-27. PubMed ID: 15681856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tight junctions in thyroid carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms.
    Tzelepi VN; Tsamandas AC; Vlotinou HD; Vagianos CE; Scopa CD
    Mod Pathol; 2008 Jan; 21(1):22-30. PubMed ID: 17962811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas.
    Takano T; Ito Y; Hirokawa M; Yoshida H; Miyauchi A
    Br J Cancer; 2007 May; 96(10):1549-53. PubMed ID: 17453004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of the 2022 WHO Classification of Thyroid Neoplasms.
    Baloch ZW; Asa SL; Barletta JA; Ghossein RA; Juhlin CC; Jung CK; LiVolsi VA; Papotti MG; Sobrinho-Simões M; Tallini G; Mete O
    Endocr Pathol; 2022 Mar; 33(1):27-63. PubMed ID: 35288841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycolysis-related protein expression in thyroid cancer.
    Nahm JH; Kim HM; Koo JS
    Tumour Biol; 2017 Mar; 39(3):1010428317695922. PubMed ID: 28347233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial markers in thyroid carcinoma: an immunoperoxidase study.
    Wilson NW; Pambakian H; Richardson TC; Stokoe MR; Makin CA; Heyderman E
    Histopathology; 1986 Aug; 10(8):815-29. PubMed ID: 2428725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse models of thyroid cancer: A 2015 update.
    Kirschner LS; Qamri Z; Kari S; Ashtekar A
    Mol Cell Endocrinol; 2016 Feb; 421():18-27. PubMed ID: 26123589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.